For instance, 8H9, 131I-monoclonal antibodies targeting B7-H3, was found to be an immunotherapeutic agent in neuroectodermal tumors, and has been tested in a phase I trial to treat patients with diffuse intrinsic pontine glioma (36, 37). This evidence concerns the gene CD276 and diffuse intrinsic pontine glioma.